Skip to Content


Active Substance: dofetilide
Common Name: dofetilide
ATC Code: C01BD04
Marketing Authorisation Holder: Pfizer Limited
Active Substance: dofetilide
Status: Withdrawn
Authorisation Date: 1999-11-29
Therapeutic Area: Atrial Flutter Atrial Fibrillation
Pharmacotherapeutic Group: Cardiac therapy

Therapeutic Indication

Tikosyn is a Class III antiarrhythmic agent that is indicated for the following:

  • Conversion of persistent atrial fibrillation or atrial flutter to normal sinus rhythm in patients in whom cardioversion by electrical means is not appropriate and in whom the duration of the arrhythmic episode is less than 6 months (see section 5.1).
  • Maintenance of sinus rhythm (after conversion) in patients with persistent atrial fibrillation or atrial flutter. Because TIKOSYN can cause ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic and in whom other antiarrhythmic therapy is not appropriate.

Dofetilide has not been shown to be effective in patients with paroxysmal atrial arrhythmias (including paroxysmal atrial fibrillation).

The marketing authorisation for Tikosyn has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.